• Adult patients with generalized Myasthenia Gravis (age 18-75 years)

• Positive serology testing for AChR+ antibody at screening

• Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG and likely not in need v of a respirator for the duration of the study, as judged by the Investigator.

• The confirmation of the diagnosis of gMG should be documented and supported by ≥1 of the following 3 tests:

• History of abnormal neuromuscular transmission demonstrated by single-fiber electromyography or repetitive nerve stimulation.

• History of positive edrophonium chloride test

• Patient has demonstrated improvement in MG signs on oral acetylcholinesterase inhibitors as assessed by the treating physician.

• Baseline MG-ADL score ≥6, with ≥50% of the total score due to non-ocular symptoms

• Participants not optimally controlled for ≥ 6 months on

• just one NSIST; or

• two or more NSISTs; or

• on frequent (at least quarterly) plasmapheresis, plasma exchange, or intravenous immunoglobulin to control symptoms despite treatment with steroids and NSISTs; or

• one of the following gMG treatments:

• a FcRN antagonist approved for gMG

• rituximab

• other approved gMG therapies excluding complement inhibitors.

• Consistent with all other iptacopan trials, participants will have to be vaccinated against Neisseria meningitidis and Streptococcus pneumoniae. In addition, participants will be vaccinated against Haemophilus influenzae, depending on the local regulations and on the availability of this vaccine in the countries of study conduct. The vaccination will be performed at least 2 weeks prior to first dosing with iptacopan, covering as many serotypes as possible. If iptacopan treatment will start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment must be initiated and administered until 2 weeks post vaccination.